The proposed bill C-17 to modernize the Canadian Food and Drugs Act has received media attention mainly with respect to its implications on drug safety. It will provide the government with more powers, including the power to recall drugs from the market. However, bill C-17 also applies to medical devices, including software-based medical devices. The bill also puts in place a mandatory reporting requirement of adverse events using drugs and medical devices. This is a step in the right direction. Now all me need is a budget to empower the government to enforce the new regulation.